Argenica Therapeutics
ASX:AGNPerth, Australia· Est.
Australian‑stage biotech delivering a first‑responder neuroprotective therapy for stroke and acute brain injury.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileAI Company Overview
Australian‑stage biotech delivering a first‑responder neuroprotective therapy for stroke and acute brain injury.
NeurologyCNS Injury
Technology Platform
Cationic, arginine‑rich peptide that stabilizes neuronal membranes, reduces excitotoxicity and modulates inflammation to protect brain tissue after acute injury.
Opportunities
First‑responder administration of a neuroprotective therapy addresses a large unmet need and could capture a multi‑billion‑dollar stroke market, with potential expansion to other acute CNS injuries.
Risk Factors
Clinical trial failure, high development costs for Phase 3, and competition from other neuroprotective candidates could impede commercialization.
Competitive Landscape
Few agents have demonstrated efficacy in acute neuroprotection; ARG‑007’s peptide‑based mechanism and pre‑hospital delivery differentiate it from small‑molecule and antibody approaches.